晚期胆管细胞癌的治疗现状与进展  

Current status and progress in the treatment of advanced cholangiocarcinoma

作　　者：汪跞 何梦烨[1] 沈朋[1] Luo Wang;Mengye He;Peng Shen(Department of Medical Oncology,The First Affiliated Hospital Zhejiang University School of Medicine,Hangzhou 310003,China)

机构地区：[1]浙江大学医学院附属第一医院肿瘤内科

出　　处：《中国肿瘤临床》2019年第21期1130-1134,共5页Chinese Journal of Clinical Oncology

摘　　要：胆管细胞癌近年来发病率有升高趋势,我国胆管癌患者约占全球总体胆管恶性肿瘤例数一半。对于晚期胆管细胞癌来说,目前治疗方式不再局限于姑息性手术和吉西他滨联合顺铂的化疗,肝动脉灌注法等局部疗法以及针对胆管细胞癌特异性靶点或多突变位点的靶向治疗和免疫治疗的出现,使得一线药物失效后,还可以采用不良反应相对较小的个体化治疗,使患者获得更长的生存时间和更高的生活质量。在此,本文总结了胆管细胞癌目前常见治疗方式以及靶向治疗和免疫治疗进展,以期为临床实践提供参考。The morbidity of cholangiocarcinoma has increased in recent years,and the number of Chinese patients with the condition accounts for half of the global number of patients.The treatment for advanced cholangiocarcinoma is no longer limited to palliative surgery;currently,chemotherapy with gemcitabine and cisplatin is used.With the emergence of local therapy(such as hepatic artery perfusions),targeted therapy for specific or multiple mutations,and immunotherapy treatments available after failure of first-line drugs,individualized treatments with relatively mild adverse reactions are now available that provide longer survival time and better quality of life.Here,we summarize the current status of common treatment methods for cholangiocarcinoma and the progress of novel targeted therapies and immunotherapies,with an aim to provide references for clinical practice.

关 键 词：晚期胆管细胞癌 治疗 

分 类 号：R735.8[医药卫生—肿瘤]